SUZUKEN : Notice Concerning Revisions to Earnings Forecasts(55KB)
October 31, 2014 at 04:55 am EDT
Share
Press Release
Suzuken Co., Ltd.
Hiroshi Ota, President and CEO (Stock Code: 9987)
October 28, 2014
Securities Traded: First Sections of the Tokyo and Nagoya Stock Exchanges, and the Sapporo Securities Exchange
Contact: Takahito Ito, Vice President and Executive Officer
Tel.: +81-52-961-2331
Notice Concerning Revisions to Earnings Forecasts
Based on recent trends in business results, Suzuken Co., Ltd. ("Suzuken") has revised, as follows, its cumulative earnings forecasts for the second quarter of the fiscal year ending March 31, 2015, which were announced on May 9, 2014.
1. Revision of Cumulative Forecasts for the Second Quarter of the Fiscal Year Ending March 31,
2015 (April 1, 2014 to September 30, 2014)
Net Sales
Operating
Income
Ordinary
Income
Net Income
Net Income per
Share
Previous Forecast (A)
Millions of yen
960,100
Millions of yen
1,090
Millions of yen
8,810
Millions of yen
5,070
Yen
56.24
Revised Forecast (B)
939,100
2,680
10,740
6,660
73.88
Change (B-A)
(21,000)
1,590
1,930
1,590
Change (%)
(2.2)
145.9
21.9
31.4
[Reference] Cumulative Results for the Previous Second Quarter
(Second Quarter of the Fiscal
Year Ended March 31, 2014)
958,485
3,850
12,229
7,919
87.85
2. Reasons for the Revision
Net sales are expected to fall short of the previous forecast. This is mainly because the government promoting the use of generic drugs is having an impact primarily on the Pharmaceutical Distribution business.
On the other hand, operating income and net income are projected to exceed the previous forecasts. This is mainly for the reason Suzuken endeavored to curtail selling, general and administrative expenses.
Due to the uncertain market outlook, Suzuken has not changed its full-term consolidated earnings forecasts announced on May 9, 2014.
Note: The earnings forecasts above were prepared based on information available as of the date this data was announced. Actual earnings may differ from the forecast figures due to various factors that may arise in the future.
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.
SUZUKEN CO., LTD. 
